

Review of: "[Research Note] Semaglutide, a GLP-1 Agonist Like Ozempic, and Its Potential Role as a Preventive Anti-Cancer Agent"

Priyanka Choudhury¹

¹ Medical College of Wisconsin

Potential competing interests: No potential competing interests to declare.

The manuscript is interesting and well-written. However, I do have a minor suggestion:

Please mention the dose range of GLP-1 agonists for anti-diabetic and anticancer effects.

The molecular mechanisms of GLP-1 agonists for the anti-diabetic effect are well known. If possible, please explain the molecular mechanisms of the anti-cancer effects of GLP-1 agonists.